Ani Pharmaceuticals (ANIP) Change in Account Payables (2012 - 2026)

Ani Pharmaceuticals has disclosed Change in Account Payables across 15 years of filings, most recently posting $5.4 million for Q1 2026.

• Change in Account Payables for Q1 2026 came in at $5.4 million, down 3.44% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.0 million (up 372.19% YoY), and the FY2025 annual result was $15.2 million, up 3064.09% from the prior year.
• Change in Account Payables came in at $5.4 million for Q1 2026 at Ani Pharmaceuticals, up from -$7.2 million in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $13.8 million in Q3 2025 to a low of -$9.1 million in Q3 2022.
• The 5-year median for Change in Account Payables is $3.1 million (2025), against an average of $2.0 million.
• Peak annual rise in Change in Account Payables reached 753.23% in 2022, while the deepest fall reached 602.32% in 2022.
• Ani Pharmaceuticals' Change in Account Payables stood at $10.1 million in 2022, then tumbled by 72.38% to $2.8 million in 2023, then sank by 345.36% to -$6.8 million in 2024, then dropped by 6.07% to -$7.2 million in 2025, then soared by 174.06% to $5.4 million in 2026.
• The last three Change in Account Payables figures came in at $5.4 million (Q1 2026), -$7.2 million (Q4 2025), and $13.8 million (Q3 2025), per Business Quant data.